Therefore, modulation of inflammation during IAV infection by CXCR1/2 antagonists, such as DF2162, may be an interesting strategy to treat the flu and decrease the morbidity associated with secondary bacterial infections. This evidence concerns the gene CXCR1 and bacterial infectious disease.